Decorin as a multivalent therapeutic agent against cancer.

Citation data:

Advanced drug delivery reviews, ISSN: 1872-8294, Vol: 97, Page: 174-85

Publication Year:
2016
Usage 72
Downloads 40
Abstract Views 30
Link-outs 2
Captures 28
Readers 28
Social Media 1
Tweets 1
Citations 17
Citation Indexes 17
Repository URL:
https://jdc.jefferson.edu/pacbfp/199
PMID:
26522384
DOI:
10.1016/j.addr.2015.10.016
PMCID:
PMC4753134
Author(s):
Neill, Thomas; Schaefer, Liliana; Iozzo, Renato V.
Publisher(s):
Elsevier BV
Tags:
Pharmacology, Toxicology and Pharmaceutics; small leucine-rich proteoglycan; autophagy; mitophagy; angiogenesis; endothelial cells; receptor tyrosine kinases; Biochemistry; Cancer Biology; Cell Biology; Molecular Biology
Most Recent Tweet View All Tweets
review description
Decorin is a prototypical small leucine-rich proteoglycan that epitomizes the multifunctional nature of this critical gene family. Soluble decorin engages multiple receptor tyrosine kinases within the target-rich environment of the tumor stroma and tumor parenchyma. Upon receptor binding, decorin initiates signaling pathways within endothelial cells downstream of VEGFR2 that ultimately culminate in a Peg3/Beclin 1/LC3-dependent autophagic program. Concomitant with autophagic induction, decorin blunts capillary morphogenesis and endothelial cell migration, thereby significantly compromising tumor angiogenesis. In parallel within the tumor proper, decorin binds multiple RTKs with high affinity, including Met, for a multitude of oncosuppressive functions including growth inhibition, tumor cell mitophagy, and angiostasis. Decorin is also pro-inflammatory by modulating macrophage function and cytokine secretion. Decorin suppresses tumorigenic growth, angiogenesis, and prevents metastatic lesions in a variety of in vitro and in vivo tumor models. Therefore, decorin would be an ideal therapeutic candidate for combating solid malignancies.